Wire · opportunities
Oneness Biotech Advances SNS851 to Phase 1 Multiple-Ascending Dose Evaluation for ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 29 September 2026 · Fusion42 review
Oneness Biotech has advanced SNS851, a novel siRNA therapy targeting liver mitochondrial activity for metabolic diseases linked to obesity, into the multiple-ascending dose Phase 1 trial segment with data expected in early 2027. SNS851 offers a different mechanism focusing on energy metabolism rather than appetite suppression and may complement or serve as a monotherapy alongside GLP-1 treatments.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 29 Sep 2026 and 30 Sep 2026.
◆ ◆ The Wire takeaway
You face a new metabolic drug option that skips appetite control and targets energy use directly; SNS851's coming data may open doors for therapy combinations or standalone use. Start talks with potential partners who want alternatives to GLP-1 weight-loss drugs.
◆ Coverage
3 sources · first reported 29 Sep 2026 · latest 30 Sep 2026
◆ Related on Wire
◆ Topics